APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth

By Michael Hahne,* Takao Kataoka,* Michael Schröter,* Kay Hofmann,§ Martin Irmler,* Jean-Luc Bodmer,* Pascal Schneider,* Tierry Bornand,* Nils Holler,* Lars E. French,† Bernard Sordat,‡ Donata R imoldi,‡ and Jürg Tschopp*

From the *Institute of Biochemistry, the †Ludwig Institute of Cancer Research, Lausanne Branch, University of Lausanne, CH-1066 Epalinges, Switzerland; the §Swiss Institute for Experimental Cancer Research, BIL Research Centre, CH-1066 Epalinges, Switzerland; and the ‡Department of Dermatology, University of Geneva, Medical School, CH-1211 Geneva 4, Switzerland

Summary

Members of the tumor necrosis factor (TNF) family induce pleiotropic biological responses, including cell growth, differentiation, and even death. Here we describe a novel member of the TNF family designated APRIL (for a proliferation-inducing ligand). Although transcripts of APRIL are of low abundance in normal tissues, high levels of mRNA are detected in transformed cell lines, and in human cancers of colon, thyroid, and lymphoid tissues in vivo. The addition of recombinant APRIL to various tumor cells stimulates their proliferation. Moreover, APRIL-transfected NIH-3T3 cells show an increased rate of tumor growth in nude mice compared with the parental cell line. These findings suggest that APRIL may be implicated in the regulation of tumor cell growth.

Key words: tumor necrosis factor • tumorigenesis • cell survival • ligand • protein

Members of the TNF cytokine family are critically involved in the regulation of infections, inflammation, autoimmune diseases, and tissue homeostasis (1). These ligands can act in a membrane-bound form or as proteolytically processed, soluble cytokines in an autocrine, paracrine, or endocrine manner (1). Binding to their respective receptors leads to the triggering of diverse signaling pathways, including the activation of caspases, the translocation of nuclear factor-κB (NF-κB), or the activation of mitogen-activated kinases such as c-Jun N H₂-terminal kinase (JNK) or extracellular signal-regulatory kinase (ERK). Thus, TNF-related ligands can lead to either apoptosis, differentiation, or proliferation (1). To date, 13 members of the TNF cytokine family have been described: TNF-α, lymphotxin (LT)α, LTβ, CD40L, CD30L, CD27L, 4-1BBL, OX40L, FasL, TRAIL/APO-2L (2, 3), TRANCE/RANKL (4, 5), LIGHT (6), and TWEAK (7).

The ligand members are type II membrane molecules. Their extracellular domains have β jelly roll topography (8), and are important in ligand trimerization. Intrinsically oligomerization is the formation of the receptor binding site at the junction between neighboring subunits, creating a multivalent ligand. The binding of the ligands to their respective receptors induces oligomerization, initiating downstream signaling events.

Here we characterize the structural and functional properties of a new ligand of the TNF cytokine family. The new ligand, termed APRIL (for a proliferation-inducing ligand), is primarily expressed in tumor tissues and can accelerate the growth of transformed cells in vitro and in vivo.

Materials and Methods

Materials. The anti-FLAG M2 mAb and the anti-FLAG M2 antibody coupled to agarose were purchased from Eastman Kodak Co. (Rochester, N.Y.). Protein A–Sepharose and CNBr-activated Sepharose were purchased from Amersham Pharmacia Biotech (Uppsala, Sweden). Cell culture reagents were obtained from Life Sciences (Basel, Switzerland). Human TWEAK cDNA was provided by Dr. J. Browning (Biogen, Inc., Cambridge, MA). FLAG-tagged soluble human TWEAK (residues 141–284) and FLAG-tagged soluble FasL were produced in 293 cells as described (9, 10).

Cells. Mouse B lymphoma A20 and human embryonic kidney cells 293 T (11) were maintained in DMEM containing 10% T. Kataoka, M. Schröter, K. Hofmann, and M. Irmler contributed equally to this work.

Materials. The anti-FLAG M2 mAb and the anti-FLAG M2 antibody coupled to agarose were purchased from Eastman Kodak Co. (Rochester, N.Y.). Protein A–Sepharose and CNBr-activated Sepharose were purchased from Amersham Pharmacia Biotech (Uppsala, Sweden). Cell culture reagents were obtained from Life Sciences (Basel, Switzerland). Human TWEAK cDNA was provided by Dr. J. Browning (Biogen, Inc., Cambridge, MA). FLAG-tagged soluble human TWEAK (residues 141–284) and FLAG-tagged soluble FasL were produced in 293 cells as described (9, 10).

Cells. Mouse B lymphoma A20 and human embryonic kidney cells 293 T (11) were maintained in DMEM containing 10%
heat-inactivated FCS. The human T lymphoblastoma Jurkat cells, colon adenocarcinoma HT-29 cells, Raji Burkitt lymphoma, and human MCF-7 cells were grown in RPMI supplemented with 10% FCS. All media contained antibiotics (penicillin and streptomycin at 5 μg/ml each and neomycin at 10 μg/ml). Other cell lines referred to in this paper are deposited in and described by the American Type Culture Collection (Rockville, MD).

Northern Blot Analysis and In Situ Hybridization. Northern blot analysis was carried out using the following membranes: human multiple tissue Northern blots I and II (7760-1 and 7759-1; Clontech, Palo Alto, CA), human cancer cell line MNT blot (7757-1; Clontech), and human tumor panel blot (D 3500-01; Invitrogen Corp., Carlsbad, CA). The membranes were incubated in ExpressHyb hybridization solution (8015-1; Clontech) for at least 1 h at 62°C. The random-primed cDNA probe (Boehringer Mannheim Corp., Indianapolis, IN) was synthesized using cDNA corresponding to the extracellular domain of APRIL as template. The heat-denatured cDNA probe was added at 1.5 × 10^6 cpm/ml in fresh ExpressHyb. The membrane was hybridized 12–24 h at 62°C, washed three times in 2× SSC containing 0.05% SDS, and exposed at −70°C to x-ray films.

For in situ hybridization, cryostat sections (6–8 μm) of primary colon carcinomas (three patients) were air dried, fixed in 4% (wt/vol) paraformaldehyde in PBS, and used immediately for immunofluorescence or stored at 70% ethanol at 4°C before in situ hybridization. In situ hybridization and immunofluorescence were performed as reported previously (12). After in situ hybridization, slides were directly exposed to x-ray films. Specificity controls included the systematic use of sense cRNA probes in each experiment.

Characterization of APRIL cDNA and Expression of Recombinant Soluble APRIL. The full-length APRIL gene (sequence data available from EMBL/GenBank/DDBJ under accession no. AF046888) was contained in the expressed sequence tag (EST) clones AA292304 and AA292358. EST clone AA292304 was used to amplify the coding region of APRIL using a specific 5′ forward primer flanked by an EcoRI site (5′-CCAGCCTCTACT-GCCCTTGTC-3′) and a specific 3′ reverse primer flanked by an XbaI site (5′-TCACAGTTTCAACACCG-GG-3′). The amplified fragment was cut with EcoRI/XbaI and cloned into a modified version of pcRIII (Invitrogen Corp.), in frame with an N7b-terminal FLAG peptide (9). The soluble form of APRIL (sAPRIL) was generated using the two primers 5′-AAACAGAA-GAAGCAGCACTCT-GCCCTTGTC-3′ and 5′-TCACAGTTTCAACACCG-GG-3′ containing a PstI and XbaI site, respectively, and subsequently cloned into a modified pcRIII vector containing both a hemagglutinin signal for protein secretion in eukaryotic cells and an N7b-terminal FLAG epitope (9). Purification of FLAG-tagged APRIL was affinity-purified on anti-FLAG M2 antibody coupled to agarose.

Proliferation Assays. The proliferation of cells was determined by incubating 5 × 10^4 cells/well in 100 μl medium with the indicated concentrations of recombinant sAPRIL, sTWEAK, and sFasL. Cell proliferation was determined using the Celltiter 96 AQ proliferation assay (Promega Corp., Madison, WI) after 24 h, following the manufacturer's instructions. Alternatively, cells were pulsed for 4 h with [3H]thymidine (0.5 μCi/well), exposed to three cycles of freezing and thawing, and harvested. [3H]thymidine incorporation was monitored by liquid scintillation counting. For the immunodepletion of FLAG-APRIL, anti-FLAG antibodies coupled to agarose (Eastman Kodak Co.) were used.

Cell Lines Stably Expressing APRIL. The full-length FLAG-tagged APRIL containing pcRIII expression vector was transduced into NIH-3T3 cells using the calcium phosphate method of transfection. 48 h after transfection, cells were seeded at 10^4 cells/well in flat-bottomed 96-well plates under selection with 800 μg/ml G418 (Sigma Chemical Co., St. Louis, MO). Cell extracts of stable clones were electrophoretically separated by SDS-PAGE under reducing conditions and subsequently transferred to nitrocellulose. Immunoblots of FLAG-tagged APRIL were probed using 5 μg/ml of anti-FLAG M2 mAb and the ECL system (Amersham Pharmacia Biotech).

Tumor Growth in Mice. NIH-3T3 fibroblasts (American Type Culture Collection) and the various transfectants (10 cells) were suspended in 50 μl PBS and injected subcutaneously into the flank region of BALB/c nude mice (Harlan Nederland, Zeist, The Netherlands). Mice were sex- and age-matched.

Results and Discussion

APRIL Is a Novel Ligand of the TNF Family. All TNF ligand/receptor family members characterized to date are biologically important. Therefore, we screened public databases using an improved profile search (13) based on an optimal alignment of all currently known TNF ligand family members. Several candidate clones were found coding for a unique, novel TNF-α-related ligand which we termed APRIL (for a proliferation-inducing ligand). Two of these cDNA clones (AA292358 and AA292304) contained full-length sequences (1.5 and 1.7 kb, respectively) encoding a protein of 250 amino acids, with a predicted cytoplasmic domain of 28 amino acids, a hydrophobic transmembrane region, and an extracellular domain of 201 amino acids (Fig. 1 A). The absence of a signal peptide suggested that APRIL was a type II membrane protein which is typical of the members of the TNF ligand family. The single N-linked glycosylation site (N124) predicted for this protein lies within the first of several β strands which are folded into an antiparallel β sandwich structure (14). The sequence of the extracellular domain of APRIL showed highest homology with FasL (21% amino acid identity), TNF-α (20%), and LTβ (18%), followed by TRAIL, TWEAK, and TRANCE (15%) (Fig. 1 B).

Expression of APRIL mRNA in Tumors. Northern blot analysis of APRIL revealed that the expression of APRIL was weak and restricted only to a few tissues (Fig. 2 A). Two transcripts of 2.1 and 2.4 kb were found in the prostate, whereas a shorter 1.8-kb transcript was found in PBLs. A longer exposure time of the Northern blot revealed that the 2.1-kb APRIL mRNA was also present in colon, spleen, and pancreas (data not shown). This restricted distribution of the APRIL mRNA was consistent with the origin of cDNA clones currently available in the EST database. Of the 23 clones identified, only two were derived from normal tissues (pregnant uterus and pancreatic islet cells). Remarkably, the remainder of the EST clones (21 clones, 91%) were present in cDNA libraries generated from tumors or tumor-derived cell lines (ovary tumor, 11%; prostate tumor, 3; Gessier Wilms tumor, 1; colon carcinoma, 1; endometrial tumor, 1; parathyroid tumors, 1; pancreas tumor, 1; T cell lymphoma, 1; LN CAP adenocar-
cinoma–derived cell line, 1). This is in contrast to TNF–α, where only 16% of EST clones were tumor-derived. This prompted us to test transformed cell lines for the expression of APRIL mRNA (Fig. 2 B), and indeed, all tumor cell lines strongly expressed the 2.1-kb transcript of APRIL. The highest APRIL-specific signals were detected in the colorectal adenocarcinoma SW480, the Burkitt's lymphoma Raji, and the melanoma G361 cell lines.

To corroborate this finding, we measured APRIL mRNA expression levels in several tumors and compared them to normal tissues. APRIL mRNA was elevated in thyroid carcinoma and in lymphoma, whereas in the corresponding normal tissues, hybridization signals were either weak or absent (Fig. 2 C). In the two other tumors analyzed by Northern blots (adrenal and parotid carcinoma), APRIL mRNA was not increased. By in situ hybridization, highly increased levels of APRIL mRNA were also detected in human colon adenocarcinomas of three different patients compared with normal colon tissue (Fig. 2 D).

APRIL Enhances Tumor Cell Proliferation. To explore the possible activities of APRIL, we expressed a FLAG-tagged form of the soluble extracellular domain of APRIL (sAPRIL) encompassing amino acids 110–250 in 293 cells. The widespread expression of APRIL in tumor cells and tissues suggested to us that APRIL may be associated with tumor growth, and we therefore incubated various tumor

Figure 1. (A) Predicted amino acid sequence of human APRIL. The predicted transmembrane region (TM, boxed), the potential N-linked glycosylation site (O), and the NH₂ terminus of the recombinant sAPRIL are indicated. (B) Comparison of the extracellular protein sequence of APRIL and some members of the TNF ligand family. Identical and homologous residues are represented in black and shaded boxes, respectively. TNFα, TNF–α, LTα, LTα.
cell lines with purified recombinant sAPRIL. An increase in proliferation of the Jurkat T lymphoma cells in the presence of APRIL was observed in a dose-dependent manner as detected by an increase in the number (50%) of viable cells 24 h after ligand addition (Fig. 3A). As expected, the addition of identically produced and purified FasL to Jurkat cells decreased the number of viable cells, whereas TWEAK had no effect. The increased cell number correlated with augmented (40%) [3H]thymidine incorporation in APRIL-treated cells (Fig. 3B). Differences in growth rates of Jurkat cells exposed to APRIL and TWEAK were already apparent after 12 h of incubation, and after 36 h the number of Jurkat cells had almost doubled (Fig. 3B). Immunodepletion of FLAG-tagged APRIL-containing medium by anti-FLAG antibodies, but not by antimyc antibodies (D) Influence of FC5 concentration on APRIL-induced proliferation of Jurkat cells. Data are the means ± SEM of triplicate determinations.

Figure 3. APRIL stimulates cell growth. (A) Dose-dependent stimulation of proliferation of Jurkat cells (human leukemic T cells), determined 24 h after the addition of sAPRIL. Controls include cells treated with FasL, TWEAK, and no ligand (Control). (Left) Number of viable cells; middle, [3H]thymidine incorporation; right, kinetic analysis of the effect of APRIL on Jurkat cells. The concentrations of ligands are indicated. (B) Effect of APRIL on the proliferation rate of Raji (human Burkitt lymphoma), A20 (mouse B lymphoma), BJAB (human B lymphoma), COS (SV40-transformed monkey kidney cells), MCF-7 (human breast adenocarcinoma), HELa (human embryonic lung), and ME260 (human melanoma). (C) Influence of immunodepletion of FLAG-tagged APRIL on tumor cell growth. The proliferative effect of FLAG-tagged APRIL is neutralized by Sepharose-bound anti-FLAG antibodies, but not by anti-myc antibodies. (D) Influence of FC5 concentration on APRIL-induced proliferation of Jurkat cells. Data are the means ± SEM of triplicate determinations.

APRIL is linked to the TNF/LT locus in the MHC.

The mechanism by which APRIL increases cellular proliferation of transformed cells is currently unknown. APRIL does not appear to activate NF-κB or c-Jun N terminal...
kinase, and the cell cycle analysis of APRIL-treated cells remains unperturbed (data not shown). Moreover, the histochemical analysis of tumors induced by APRIL-transfected NIH-3T3 cells did not reveal any apparent morphological differences compared with wild-type NIH-3T3 tumors, suggesting that APRIL is not angiogenic. Thus, it will be important to identify and characterize the receptor for APRIL (recombinant sAPRIL does not interact with Fas, LTβR, HVEM, TNFR-1, TNFR-2, GITR, TRAIL-R1, TRAIL-R2, or TRAIL-R3; data not shown).

The development of cancer is viewed as a multistep process, involving mutation and selection for cells with progressively increasing capacity for proliferation, survival, and invasion, even under conditions where the growth factor (blood) supply is limited. APRIL allows tumor cells to proliferate at a reasonable rate even in low serum conditions (see Fig. 3D). Given that APRIL is strongly expressed in several types of tumors and that it stimulates cell proliferation in vitro and in vivo, it is possible that APRIL may play a role in tumorigenesis. Therefore, antagonistic antibodies to APRIL or the APRIL receptor may have a potential for cancer treatment.

We thank S. Hertig and G. Radigruber for technical assistance, S. Belli for reading the manuscript, and Dr. Jeffrey Browning for helpful discussions.

This work was supported by grants from the Swiss National Science Foundation.

Address correspondence to Dr. Jürg Tschopp, Institute of Biochemistry, University of Lausanne, Ch. des Boveresses 155, CH-1066 Epalinges, Switzerland. Phone: 41-21-692-5738; Fax: 41-21-692-5705; E-mail: jurg.tschopp@ib.unil.ch

Received for publication 30 March 1998 and in revised form 4 May 1998.

References

1. Smith, C.A., T. Farrah, and R.G. Goodwin. 1994. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 76:959–962.
2. Wiley, S.R., K. Schooley, P.J. Smolak, W.S. Din, C.P. Huang, J.K. Nicholl, G.R. Sutherland, T.D. Smith, C. R auch, C.A. Smith, and R.G. Goodwin. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673–682.
3. Pitti, R.M., S.A. Marsters, S. Ruppert, C.J. Donahue, A. Moore, and A. Ashkenazi. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271:12687–12690.
4. Anderson, D.M., E. Maraskovsky, W.L. Billingsley, W.C. Dougal, M.E. Tometsko, E.R. Roux, M.C. Teepe, R.F. DuBose, D. Cosman, and L. Galibert. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 390:175–179.
5. Wong, R., J. Rho, J. Arron, E. Robinson, J. Orlinick, M. Chao, S. Kalachikov, E. Cayani, F. Bartlett, W. Frankel, et al. 1997. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272:25190–25194.
6. Mauri, D.N., R. Ebener, R.I. Montgomery, K.D. Kochel, T.C. Cheung, G. Yu, S. Ruben, M. Murphy, R.J. Eisenberg, G.H. Cohen, et al. 1998. LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator. Immunity. 8:21–30.
7. Chicheportiche, Y., P.R. Bourdon, H. Xu, Y.M. Hsu, H. Scott, C. Hession, I. Garcia, and J.L. Browning. 1997. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 272:32401–32410.
8. Banner, D.W., A. D’Arcy, W. Janes, R. Gentz, H.J. Schoenfeld, C. Broger, H. Loetscher, and W. Lesslauer. 1993. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell. 73:431–445.

9. Schneider, P., J.L. Bodmer, N. Holler, C. Mattmann, P. Scuder, A. Terskikh, M.C. Peitsch, and J. Tschopp. 1997. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J. Biol. Chem. 272:18827–18833.

10. Schneider, P., N. Holler, J.L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1205–1213.

11. Hahne, M., D. Rimoldi, M. Schröter, P. Romero, M. Schreier, L.E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, et al. 1996. Melanoma cell expression of FasApo-1(CD95) ligand: implications for tumor immune escape. Science. 274:1363–1366.

12. French, L.E., M. Hähne, I. Viard, G. Radlgruber, R. Zanone, K. Becker, C. Muller, and J. Tschopp. 1996. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol. 133:335–343.

13. Bucher, P., K. Karplus, N. Moeri, and K. Hofmann. 1996. A flexible search technique based on generalized profiles. Comput. Chem. 20:3–23.

14. Bucher, P., A. D’Arcy, W. Janes, R. Gentz, H.J. Schoenfeld, C. Broger, H. Loetscher, and W. Lesslauer. 1993. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell. 73:431–445.

15. Tartaglia, L.A., and D.V. Goeddel. 1992. Two TNF receptors. Immunol. Today. 13:151–153.

16. Tracey, K.J., and A. Cerami. 1994. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 45:491–503.